@FiercePharma: ICYMI: Adding Opdivo to Yervoy ups melanoma treatment efficacy--but it ups rate of serious side effects, too. Report | Follow @FiercePharma
@CarlyHFierce: UPDATED w/Genentech comment: Roche's Gazyva doubles remission time for non-Hodgkin lymphoma patients. Story | Follow @CarlyHFierce
> No sooner had England's cost-effectiveness watchdogs issued a preliminary rejection to AstraZeneca's ($AZN) ovarian cancer drug Lynparza than Cancer Research UK stepped up to criticize it. Report
> Actavis ($ACT) wrapped up its £306 million buyout of niche U.K. drugmaker Auden Mckenzie. Release
> The health insurer Anthem ($WLP) says its new method for reimbursing cancer treatment has helped push doctors to use recommended regimens. Report
> India's retail drug-sellers plan a nationwide campaign against online medication sales. Report
> Foster Farms says it plans to mostly eliminate antibiotics used to treat human illnesses in its poultry. Report
> Teva Pharmaceutical ($TEVA) rolled out its generic version of Actonel, the osteoporosis med, and has 180-day exclusivity on the copy. Report
Medical Device News
@FierceMedDev: ICYMI: DOJ slaps Olympus with a subpoena over dirty duodenoscopes. Article | Follow @FierceMedDev
@VarunSaxena2: FMD exclusive (got insider tip): Zimmer to cut some staff as it barrels toward merger with Biomet. Story | Follow @VarunSaxena2
@EmilyWFierce: ICYMI from FiercePharma: Otsuka faces the music for generic Abilify, loses battle with FDA. Article | Follow @EmilyWFierce
> Molecular Dx: Invitae drops prices as NIH starts 1,000-patient, molecular abnormalities cancer study. More
> Startup Arsenal Medical and its spinoff raise $26.5M to develop novel foam, nanofiber and bioresorbable products. Article
Biotech News
@FierceBiotech: ASCO 15: The top 10 setbacks, advances and head scratchers. Editor's corner | Follow @FierceBiotech
@JohnCFierce: $IMGN shares up 14% on positive early data for ovarian cancer ADC. Release | Follow @JohnCFierce
> Bristol-Myers barrels toward approval with a blockbuster cancer combo. More
> Juno amps up its CAR-T tech in drive toward a pivotal test. Report
> Bristol-Myers fires off a lawsuit to sideline R&D defector headed to rival AstraZeneca. Story
> Alzheimer's biotech eyes $300M in a scaled-up IPO. Article
Animal Health News
> Tech makers market health wearables to dog owners. Item
> Groundbreaking held for the new $1.2B NABF animal health facility in Kansas. More
> Bayer CEO Dekkers looking 'with interest' at animal-health additions. Report
> K-State researchers build avian-flu protection into existing poultry vaccine. Article
> Novozymes enters booming market for poultry probiotics. Story
Biotech IT News
> CRISPR Therapeutics starts search for a bioinformatics chief. More
> Bioinformatics leads UCSD team to ovarian cancer biomarkers. Story
> AstraZeneca's Definiens rolls out biomarker data service. Item
> Artificial intelligence tops Google VC's list of high-potential life sci techs. Article
> UT Southwestern snags $5.6M grant to boost bioinformatics operation. Report
Pharma Marketing News
> Stars of cancer meeting set to crack top 10 cancer sales by 2020. Article
> Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA. Report
> Novartis rolls out 'life hacks' for MS patients with new Live Like You campaign. Article
> ASCO must-reads: Pfizer's Ibrance; BMS, Novartis melanoma meds; J&J's Imbruvica and more. More
> Abbott takes Pedialyte on the festival circuit as grown-up hangover remedy. Story
And Finally... The high-protein versus low-fat debate plays out in Dean Ornish scuffle in Scientific American. Report